News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
266,688 Results
Type
Article (14192)
Company Profile (282)
Press Release (252214)
Section
Business (79602)
Career Advice (153)
Deals (13249)
Drug Delivery (35)
Drug Development (50442)
Employer Resources (31)
FDA (5716)
Job Trends (5132)
News (144497)
Policy (10033)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (11)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (7)
2024 Genetown Standard (7)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (4)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (3)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
Academia (910)
Accelerated approval (2)
Adcomms (12)
Allergies (49)
Alliances (21646)
ALS (60)
Alzheimer's disease (824)
Antibody-drug conjugate (ADC) (86)
Approvals (5731)
Artificial intelligence (108)
Autoimmune disease (10)
Automation (5)
Bankruptcy (104)
Best Places to Work (4565)
BIOSECURE Act (5)
Biosimilars (40)
Biotechnology (232)
Bladder cancer (43)
Brain cancer (19)
Breast cancer (139)
Cancer (1289)
Cardiovascular disease (105)
Career advice (132)
Career pathing (2)
CAR-T (107)
Cell therapy (305)
Cervical cancer (8)
Clinical research (40871)
Collaboration (497)
Compensation (218)
Complete response letters (13)
COVID-19 (1034)
CRISPR (36)
C-suite (141)
Cystic fibrosis (76)
Data (1346)
Denatured (11)
Depression (28)
Diabetes (125)
Diagnostics (1295)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (77)
Drug pricing (28)
Drug shortages (3)
Duchenne muscular dystrophy (81)
Earnings (29692)
Editorial (17)
Employer branding (4)
Employer resources (29)
Events (48125)
Executive appointments (396)
FDA (6333)
Featured Employer (31)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (464)
Gene editing (87)
Generative AI (9)
Gene therapy (228)
GLP-1 (353)
Government (1075)
Grass and pollen (2)
Guidances (18)
Healthcare (6603)
Huntington's disease (21)
IgA nephropathy (20)
Immunology and inflammation (79)
Indications (18)
Infectious disease (1096)
Inflammatory bowel disease (110)
Inflation Reduction Act (8)
Influenza (18)
Intellectual property (55)
Interviews (17)
IPO (7281)
IRA (11)
Job creations (860)
Job search strategy (127)
Kidney cancer (6)
Labor market (4)
Layoffs (201)
Leadership (2)
Legal (1388)
Liver cancer (30)
Lung cancer (185)
Lymphoma (81)
Machine learning (1)
Management (7)
Manufacturing (115)
MASH (48)
Medical device (2592)
Medtech (2593)
Mergers & acquisitions (6254)
Metabolic disorders (363)
Multiple sclerosis (51)
NASH (13)
Neurodegenerative disease (57)
Neuropsychiatric disorders (23)
Neuroscience (1188)
NextGen: Class of 2025 (2018)
Non-profit (852)
Northern California (1535)
Now hiring (21)
Obesity (185)
Opinion (100)
Ovarian cancer (60)
Pain (40)
Pancreatic cancer (51)
Parkinson's disease (104)
Partnered (8)
Patents (109)
Patient recruitment (66)
Peanut (35)
People (25518)
Pharmaceutical (48)
Pharmacy benefit managers (5)
Phase I (14428)
Phase II (19016)
Phase III (12023)
Pipeline (687)
Podcasts (46)
Policy (36)
Postmarket research (852)
Preclinical (6060)
Press Release (30)
Prostate cancer (53)
Psychedelics (35)
Radiopharmaceuticals (212)
Rare diseases (272)
Real estate (1417)
Recruiting (12)
Regulatory (8557)
Reports (15)
Research institute (938)
Resumes & cover letters (17)
Rett syndrome (3)
RNA editing (3)
RSV (10)
Schizophrenia (55)
Series A (91)
Series B (59)
Service/supplier (1)
Sickle cell disease (37)
Southern California (1359)
Special edition (11)
Spinal muscular atrophy (117)
Sponsored (11)
Startups (1974)
State (1)
Stomach cancer (4)
Supply chain (18)
The Weekly (33)
United States (12004)
Vaccines (204)
Venture capitalists (28)
Webinars (7)
Weight loss (105)
Women's health (15)
Worklife (2)
Date
Today (61)
Last 7 days (396)
Last 30 days (1504)
Last 365 days (19998)
2025 (4620)
2024 (20556)
2023 (22416)
2022 (26832)
2021 (27838)
2020 (23389)
2019 (16237)
2018 (11751)
2017 (13757)
2016 (11849)
2015 (14371)
2014 (10407)
2013 (7488)
2012 (7536)
2011 (7616)
2010 (7433)
Location
Africa (148)
Alabama (38)
Alaska (2)
Arizona (52)
Arkansas (5)
Asia (17221)
Australia (2918)
California (3489)
Canada (1047)
China (321)
Colorado (135)
Connecticut (143)
Delaware (87)
Europe (37043)
Florida (408)
Georgia (106)
Idaho (16)
Illinois (209)
India (8)
Indiana (85)
Iowa (1)
Japan (69)
Kansas (59)
Kentucky (6)
Louisiana (3)
Maine (11)
Maryland (442)
Massachusetts (2746)
Michigan (69)
Minnesota (134)
Mississippi (1)
Missouri (22)
Montana (14)
Nebraska (4)
Nevada (15)
New Hampshire (14)
New Jersey (874)
New Mexico (12)
New York (949)
North Carolina (516)
North Dakota (4)
Northern California (1535)
Ohio (107)
Oklahoma (9)
Oregon (21)
Pennsylvania (669)
Puerto Rico (3)
Rhode Island (15)
South America (209)
South Carolina (4)
Southern California (1359)
Tennessee (25)
Texas (400)
Utah (48)
Virginia (67)
Washington D.C. (28)
Washington State (317)
Wisconsin (13)
266,688 Results for "trevi therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Trevi Therapeutics to Participate in Upcoming Conferences
Trevi Therapeutics, Inc. today announced that senior management will be attending investor, business development and medical conferences in May and June.
May 9, 2024
·
3 min read
Pharm Country
Trevi Therapeutics to Participate in Upcoming April Events
Trevi Therapeutics, Inc. today announced that senior management will attend and participate in the following events in April.
April 4, 2024
·
2 min read
Pharm Country
Trevi Therapeutics to Participate in Upcoming March Events
Trevi Therapeutics, Inc today announced that senior management will attend and participate in the following events in March.
February 28, 2024
·
2 min read
Business
Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
Trevi Therapeutics, Inc. (Nasdaq: TRVI) today announced financial results for the quarter ended March 31, 2024, as well as provided business updates.
May 7, 2024
·
8 min read
Pharm Country
Trevi Therapeutics Provides Business Updates
Trevi Therapeutics, Inc. today announced a preview of business updates.
January 4, 2024
·
5 min read
Business
Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ for the treatment of chronic cough in idiopathic pulmonary fibrosis and refractory chronic cough, announced the appointment of Margaret Garin, MD, MSCR, as Vice President of Clinical Development.
April 2, 2024
·
5 min read
Pharm Country
Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference
Trevi Therapeutics, Inc. today announced that data from the Phase 2 CANAL trial will be presented at the American Thoracic Society (ATS) 2024 International Conference being held in San Diego, CA, from May 17-22. The presentation will take place on May 19th.
April 9, 2024
·
2 min read
Business
Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates
Trevi Therapeutics, Inc. (Nasdaq: TRVI) today announced financial results for the quarter and year ended December 31, 2023, as well as provided business updates.
March 20, 2024
·
9 min read
Business
Trevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024
Trevi Therapeutics, Inc. (Nasdaq: TRVI) today announced that senior management will host a conference call and live audio webcast on Tuesday, May 7, 2024, at 4:30 p.m. ET, to provide a corporate update and review the Company’s financial results for the quarter ended March 31, 2024.
May 1, 2024
·
2 min read
Pharm Country
Trevi Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Trevi Therapeutics, Inc. today announced that Jennifer Good, President and Chief Executive Officer, will be presenting at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14, at 10:00 a.m. ET.
February 6, 2024
·
2 min read
1 of 26,669
Next
